摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

羟基乙酰肼 | 3530-14-1

中文名称
羟基乙酰肼
中文别名
羟基乙酸肼
英文名称
hydroxyacetylhydrazine
英文别名
2-hydroxyacetohydrazide;2-hydroxyacetic hydrazide;Glykolsaeure-hydrazid;hydroxyacetic acid hydrazide
羟基乙酰肼化学式
CAS
3530-14-1
化学式
C2H6N2O2
mdl
MFCD09840691
分子量
90.0818
InChiKey
LIUCWHQVLKSECA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    90-930C
  • 沸点:
    395.0±25.0 °C(Predicted)
  • 密度:
    1.311±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于丙酮、氯仿、二氯甲烷、乙酸乙酯、甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    -1.9
  • 重原子数:
    6
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    75.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2928000090
  • 包装等级:
    II
  • 危险类别:
    4.1
  • 危险性防范说明:
    P210,P240,P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P370+P378,P403+P233,P501
  • 危险品运输编号:
    1325
  • 危险性描述:
    H228,H302,H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:c558e23b7994d5603188fca86ab4d248
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Adamek, Collection of Czechoslovak Chemical Communications, 1960, vol. 25, p. 1694
    摘要:
    DOI:
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 一水合肼 作用下, 生成 羟基乙酰肼
    参考文献:
    名称:
    Curtius; Schwan, Journal fur praktische Chemie (Leipzig 1954), 1895, vol. <2>51, p. 355
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Substituted triazole derivatives as oxytocin antagonists
    申请人:Brown Daniel Alan
    公开号:US20060160786A1
    公开(公告)日:2006-07-20
    The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.
    本发明涉及公式(I)的取代三唑化合物,其用途,制备方法以及含有该化合物的组合物。这些抑制剂在包括性功能障碍在内的各种治疗领域具有用途。
  • [EN] 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH<br/>[FR] 1,2,4-TRIAZOLONES TRISUBSTITUÉES EN POSITION 2, 4 ET 5, UTILES EN TANT QU'INHIBITEURS DE DHODH
    申请人:BAYER AG
    公开号:WO2018077923A1
    公开(公告)日:2018-05-03
    The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    本发明提供了一般式(I)的三唑酮化合物,其中R1、R2、R3、R4和R5如本文所定义,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包括所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗过度增殖性疾病的药物组合物,作为唯一药剂或与其他活性成分结合使用。
  • Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor
    作者:He Tian、Wei Liu、Zhixing Zhou、Qian Shang、Yuqiang Liu、Yafei Xie、Changying Liu、Weiren Xu、Lida Tang、Jianwu Wang、Guilong Zhao
    DOI:10.3390/molecules21111543
    日期:——
    In order to systematically explore and understand the structure–activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a–1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 μM against human URAT1 for 1q vs 7.18 μM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.
    为了系统地探索和理解基于lesinurad的命中化合物(1c)的结构-活性关系(SAR),该化合物是通过将lesinurad中的S原子替换为CH2得到的,设计并合成了18个化合物(1a–1r),并对其进行了体外URAT1抑制活性测试。SAR探索发现了一个高效的柔性URAT1抑制剂1q,其活性比母体lesinurad高31倍(对于人URAT1的IC50值,1q为0.23 μM,而lesinurad为7.18 μM)。本研究发现了一种柔性分子骨架,如1q所示,这可能作为进一步开发高效URAT1抑制剂的有前景的原型骨架,并且表明lesinurad中的S原子对其URAT1抑制活性并非必需。
  • Optically Active Antifungal Azoles. III. Synthesis and Antifungal Activity of Sulfide and Sulfonamide Derivatives of (2R,3R)-2-(2,4-Difluorophenyl)-3-mercapto-1- (lH-1,2,4-triazol-1-yl)-2-butanol.
    作者:Akihiro TASAKA、Katsunori TERANISHI、Yoshihiro MATSUSHITA、Norikazu TAMURA、Ryogo HAYASHI、Kenji OKONOGI、Katsumi ITOH
    DOI:10.1248/cpb.42.85
    日期:——
    In an effort to find potent antifungal agents, optically active sulfur-containing triazole derivatives, sulfides (3) and sulfonamides (4), were prepared and evaluated for antifungal activity against Candida albicans in vitro and in vivo. The sulfides (3) were prepared by the reaction of (2R, 3R)-2-(2, 4-difluorophenyl)-3-mercapto-1-(1H, 1, 2, 4-triazol-1-yl)-2-butanol (1) with various heteroarylmethyl chlorides in the presence of sodium methoxide. The sulfonamides (4) were synthesized starting from the disulfide (15) in three steps including oxidation of the corresponding sulfenamides (17). Some of the sulfur-containing triazole derivatives (3, 4) showed strong protective effects against candidosis in mice.
    为了寻找强效的抗真菌剂,制备并评估了对光学活性含硫三唑衍生物,硫醚(3)和磺胺(4)对白色念珠菌的体外和体内抗真菌活性。硫醚(3)是通过(2R,3R)-2-(2,4-二氟苯基)-3-巯基-1-(1H,1,2,4-三唑-1-基)-2-丁醇(1)与各种杂芳基氯甲烷在甲醇钠存在下反应制备的。磺胺(4)是从二硫化物(15)开始以三个步骤合成的,包括相应亚磺酰胺(17)的氧化。一些含硫三唑衍生物(3,4)显示出对小鼠念珠菌病的强烈保护作用。
  • [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER<br/>[FR] COMPOSÉS HÉTÉROBICYCLO-SUBSTITUÉS-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE POUR LE TRAITEMENT D'UN TROUBLE DU SYSTÈME NERVEUX CENTRAL
    申请人:MERCK SHARP & DOHME
    公开号:WO2014101373A1
    公开(公告)日:2014-07-03
    Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.
    本文披露了异杂双环取代的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物,其具有对A2A受体的特异结合,并可用于定量各种具有与A2A受体结合亲和力的化合物在体内受体位点的占有率。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物